Source: Annual Congress 2004 - PG7 - Application of genomics and proteomics to pulmonary disease



Rating:

Share or cite this content

Citations should be made in the following way:
R. Wattiez (Mons, Belgium). Use of pulmonary proteomics to investigate lung disease. Annual Congress 2004 - PG7 - Application of genomics and proteomics to pulmonary disease

Member's Comments

No comment yet.

Related content which might interest you: Application of omics technologies to the identification of biomarkers for COPD Source: Annual Congress 2007 - Cell biology of asthma and COPD Year: 2007 Use of PET/CT to evaluate pulmonary inflammation and fibrosis in an animal model Source: Eur Respir J 2006; 28: Suppl. 50, 606s Year: 2006 Evaluation of recently validated non-invasive formula using basic lung functions as a new screening tool for pulmonary hypertension in patients with idiopathic pulmonary fibrosis Source: Annual Congress 2009 - Pulmonary vascular diseases Year: 2009 Novel insights into the genetics of smoking behaviour, lung function and chronic obstructive pulmonary disease in UK Biobank Source: International Congress 2015 – Asthma: emerging risk factors and current management of the patient Year: 2015 History of pulmonary tuberculosis was associated with lung microbiome change in patients with chronic obstructive pulmonary disease Source: Virtual Congress 2020 – Clinical and functional evaluation of COPD Year: 2020 Longitudinal change in non-invasive markers in interstitial lung disease associated pulmonary hypertension and correlation with invasive pulmonary haemodynamics Source: International Congress 2016 – Pulmonary hypertension in lung disease Year: 2016 Biomarkers for pulmonary hypertension in interstitial lung disease Source: Annual Congress 2011 - Pulmonary hypertension in hypoxic lung disease Year: 2011 Pulmonary hypertension in interstitial lung disease: Non-invasive assessment for detection and prognosis Source: International Congress 2016 – Clinical aspects of ILD Year: 2016 A trial of the measurement of dynamic lung compliance by the new method using photoplethysmography in patients with COPD and pulmonary fibrosis Source: International Congress 2016 – The future of lung function is beginning now Year: 2016 Different definitions of pulmonary hypertension in interstitial lung disease: a prognostic evaluation. Source: Virtual Congress 2020 – Pulmonary hypertension in lung diseases Year: 2020 Imaging techniques in the evaluation of small airways in obstructive pulmonary disease Source: Research Seminar 2010 - The role of small airways in obstructive pulmonary diseases Year: 2010 Biomarkers in pulmonary hypertension associated to interstitial lung disease Source: Annual Congress 2010 - Pulmonary circulation II Year: 2010 Use of MRI for functional and structural assessment of interstitial lung disease Source: International Congress 2018 – Emerging and novel imaging biomarkers in drug-induced interstitial lung disease Year: 2018 Scleroderma lung disease: Detection of pulmonary hypertension using pulmonary function tests is problematic in patients with emphysema Source: Annual Congress 2013 –Connective tissue disease and interstitial lung disease Year: 2013 Defining severe obstructive lung disease in the biologic era: an endotype-based approach Source: Eur Respir J, 54 (5) 1900108; 10.1183/13993003.00108-2019 Year: 2019 Home monitoring of physiology and symptoms to detect interstitial lung disease exacerbations and progression: a systematic review Source: ERJ Open Res, 7 (4) 00441-2021; 10.1183/23120541.00441-2021 Year: 2021 Novel evaluation of pulmonary hypertension with chronic lung disease by perfusion SPECT/CT Source: International Congress 2019 – Pulmonary hypertension with lung diseases and experimental pulmonary hypertension Year: 2019 Fibulin-1 is a novel biomarker of disease severity in pulmonary fibrosis Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis and rarities Year: 2013